
|Articles|December 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 12
- Volume 16
- Issue 12
Encouraging Avastin results in glioblastoma multiforme
Encouraging Avastin results in glioblastoma multiforme
Advertisement
DALLASPhase II data showed 6-month progression-free survival in 36% of relapsed glioblastoma patients given Avastin (bevacizumab) alone and 51% given Avastin plus irinotecan (Camptosar), compared with historical estimates of 15%. UCLA's Timothy Cloughesy, MD, reported the findings at the Society for Neuro-Oncology annual meeting.
Articles in this issue
about 18 years ago
Third-line single-agent cetuximab ups overall survivalabout 18 years ago
Modern multislice CT propels pancreas imaging forwardabout 18 years ago
Sorafenib gets ok for liver cancerabout 18 years ago
Celgene to acquire Pharmionabout 18 years ago
Novacea halts ASCENT-2 trialabout 18 years ago
RT/temozolomide raises possibility of cure in glioblastomaabout 18 years ago
Brachytherapy as effective in younger as in older menabout 18 years ago
MMA not harming patientsabout 18 years ago
Kinase inhibitor may prevent RT-induced lung injuryabout 18 years ago
FDA approves lower starting dose for dasatinib for CMLNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
How Would the Teclistamab Combo Approval Transform Multiple Myeloma?
2
FDA Accepts NDA for Zanzalintinib/Atezolizumab in Pretreated Metastatic CRC
3
Early Time-of-Day Chemoimmunotherapy Boosts Survival in NSCLC
4
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
5



































